Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Rapid Readouts: Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer

November 1st 2021

Alexander Drilon, MD, discusses the efficacy and safety data of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer that was presented at the World Cancer Lung Conference 2021 annual meeting.

Clinical Management of RET+ Advanced NSCLC

November 1st 2021

Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.

RET Alterations in Advanced NSCLC

November 1st 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.

Larotrectinib Yields Promising Efficacy in NTRK+ Lung Cancer, Is Active Against CNS Metastases

October 30th 2021

Jessica J. Lin, MD, discussed the impact of larotrectinib in patients with NTRK fusion–positive lung cancer, and the importance of further understanding mechanism of resistance to targeted therapies.

Dr. Burns on Key Advances Made in RET+ NSCLC

October 29th 2021

Timothy F. Burns, MD, PhD, discusses key developments in the frontline treatment of patients with RET-positive non–small cell lung cancer.

Defining Trop-2 and Antibody-Drug Conjugates in NSCLC

October 29th 2021

Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, define Trop-2 in relation to treatments for non-small cell lung cancer and discuss what antibody-drug conjugates are being developed to target it.

Dr. Girard on the Next Steps With Durvalumab in NSCLC

October 29th 2021

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Dr. Johnson on the Potential of TROP2 as a Target for All-Comers With Solid Tumors

October 29th 2021

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

CT-Based Imaging Demonstrates Utility for Early COVID-19 Identification in Lung Cancer

October 29th 2021

Routine computed tomography-based imaging scans identified abnormal ground-glass opacities and infiltrates indicative of COVID-19 in patients with lung cancer undergoing radiation therapy, enabling earlier diagnosis, treatment, and risk reducing measures.

Hollings Researcher Finds Surprising Results in COVID-19-Positive Lung Cancer Patients

October 29th 2021

MUSC Hollings Cancer Center researcher and radiation oncologist Graham Warren, MD, PhD, published a new study in the Journal of Thoracic Oncology detailing new findings and early markers of COVID-19 in lung cancer patients.

Dr. Subramanian on the Current Standard of Care in Stage III NSCLC

October 29th 2021

Janakiraman Subramanian, MD, discusses the standard of care in stage III non–small cell lung cancer.

Selecting First-line Treatment for EGFR-Mutant NSCLC

October 29th 2021

Heather Wakelee, MD, shares insight on factors to consider when approaching the optimal first-line therapy for patients with EGFR-mutant advanced NSCLC.

Treatment Landscape for EGFR-Mutant Advanced NSCLC

October 29th 2021

Ani Balmanoukian, MD, Sandip P. Patel, MD, and Heather Wakelee, MD, review currently available treatment options for EGFR-mutant advanced NSCLC and discuss their approach to frontline therapy.

Dr. Villaruz on Updates From the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

October 28th 2021

Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer.

Dr. Santos on Identifying Mechanisms of Resistance in Lung Cancer

October 28th 2021

Edgardo S. Santos, MD, FACP, discusses the importance of identifying mechanisms of resistance in lung cancer.

Antibody-Drug Conjugates Take Center Stage in NSCLC

October 28th 2021

Melissa Johnson, MD, discusses highlights from the 2021 ESMO Congress.

NSCLC: Overcoming Barriers to Testing and Molecular Profiling

October 28th 2021

Erminia Massarelli, MD, MS, PhD, shares insight on potential barriers to appropriate molecular testing in patients with non–small cell lung cancer.

The Evolving Landscape of Molecular Testing for NSCLC

October 28th 2021

Experts take a broad look at how molecular profiling has impacted the treatment landscape of non–small cell lung cancer.

Dr. Simon on the Importance of Next-Generation Sequencing in NSCLC

October 27th 2021

George Simon, MD, FACP, FCCP, discusses the importance of next-generation sequencing in patients with non–small cell lung cancer.

Dr. Raez on the Clinical Implications of the KEYNOTE-024 Trial in NSCLC

October 27th 2021

Luis E. Raez, MD, discusses the clinical implications of the phase 3 KEYNOTE-024 trial in non–small cell lung cancer.